Dr Paul Marks place on Cellceutix SAB
This article was originally published in Scrip
Executive Summary
Cellceutix, a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, has appointed Dr Paul Marks to its scientific advisory board. Dr Marks served as president and CEO of Memorial Sloan-Kettering Cancer Center from 1980-1999, and remains a part of MSKCC as president emeritus and a member of the Sloan-Kettering Institute. Dr Marks joins Cellceutix just as the company has filed foreign patent applications relating to its anti-cancer compound Kevetrin for the treatment of cancer.